Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBITDA (2016 - 2025)

Historic EBITDA for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.3 million.

  • Utah Medical Products' EBITDA fell 5485.49% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 3220.09%. This contributed to the annual value of $12.6 million for FY2024, which is 2992.34% down from last year.
  • Per Utah Medical Products' latest filing, its EBITDA stood at $2.3 million for Q3 2025, which was down 5485.49% from $4.9 million recorded in Q2 2025.
  • Utah Medical Products' 5-year EBITDA high stood at $6.9 million for Q4 2022, and its period low was $884000.0 during Q4 2024.
  • Moreover, its 5-year median value for EBITDA was $3.4 million (2021), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Utah Medical Products' EBITDA soared by 32981.19% in 2021, and later tumbled by 8428.72% in 2024.
  • Quarter analysis of 5 years shows Utah Medical Products' EBITDA stood at $4.1 million in 2021, then soared by 67.53% to $6.9 million in 2022, then dropped by 19.0% to $5.6 million in 2023, then crashed by 84.29% to $884000.0 in 2024, then soared by 155.09% to $2.3 million in 2025.
  • Its EBITDA was $2.3 million in Q3 2025, compared to $4.9 million in Q2 2025 and $3.8 million in Q1 2025.